FASENRA Regulatory Postmarketing Surveillance in Korea
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
51actual
Sites
5
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-11 | actual | When the study began enrolling |
| Primary completion | 2025-03-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-06 | actual | The whole study's end, after follow-up |
| First posted | 2021-10-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
Primary outcomes
what the primary-completion date above is the date OFPercentage (%) of AEs and SAEs in patients who are treated with FASENRA
measured 24 or 48 weeks
Nature (type) of AEs in patients who are treated with FASENRA
measured 24 or 48 weeks
Incidence of AEs in patients who are treated with FASENRA
measured 24 or 48 weeks
Severity of AEs in patients who are treated with FASENRA
measured 24 or 48 weeks
Nature of unexpected adverse drug reactions in patients who are treated with FASENRA
measured 24 or 48 weeks
Incidence of unexpected adverse drug reactions in patients who are treated with FASENRA
measured 24 or 48 weeks
Severity of unexpected adverse drug reactions in patients who are treated with FASENRA
measured 24 or 48 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed